Skip to content
Assyro AI
Orange Book drug · Generic (ANDA)

Amoxicillin And Clavulanate Potassium

Amoxicillin; Clavulanate Potassium

ANDA 065063 Sandoz
Approved
Mar 14, 2002
Strengths
1
Listed patents
0
Applications
41

What does the FDA Orange Book show for Amoxicillin And Clavulanate Potassium?

Amoxicillin And Clavulanate Potassium contains Amoxicillin; Clavulanate Potassium and appears in 41 FDA Orange Book applications. ANDA 065063 is the lead filing, with 1 presentation shown in detail; the other exact-name filings are listed separately. The page preserves strength, dosage form, route, status, RLD/RS, TE, patent, and exclusivity facts. Clinical labeling requires an exact application-matched source.

FDA applications
41; lead ANDA 065063

Every filing shown uses the exact FDA product name; the lead filing supplies the detailed presentation view.

Lead application holder
Sandoz Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
1

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
AB

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
0

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
001875MG;EQ 125MG BASETABLETORALPrescriptionAB
RS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Sandoz Inc

The Orange Book identifies this organization as the applicant responsible for ANDA 065063.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

1 presentation listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

TE code AB across rated presentations

An AB code is an A-rating: FDA considers the product therapeutically equivalent to pharmaceutical equivalents in the same Orange Book heading and equivalence group.

Patent & exclusivity record

No listed patents or exclusivity records

This means none appear for this application in the current Orange Book files. It is not a freedom-to-operate opinion and does not rule out unlisted patents, regulatory barriers, or product-specific rights.

Same-ingredient landscape

0 other ANDAs and 8 other NDAs found

0 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

ANDA 065063 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue ANDA-065063

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Product detail

ANDA 065063
TE ABRS
Strength
875MG;EQ 125MG BASE
Dosage form
TABLET
Route
ORAL
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    24 yr 9 mo ago

  2. Today

Pharmaceutical detail

FDA product record

Active ingredient

AMOXICILLIN; CLAVULANATE POTASSIUM

Strength

875MG;EQ 125MG BASE

Dosage form

TABLET

Route

ORAL

TE code

AB

Application

ANDA 065063

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

No

Reference standard (RS)

Yes

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Other FDA applications for Amoxicillin And Clavulanate Potassium

40 additional filings · 40 generic

The FDA has approved 41 separate applications under this product name. Each row is one application: a distinct applicant and approval for the same drug.

Other FDA applications approved under the product name Amoxicillin And Clavulanate Potassium, with applicant, approval date, number of strengths, therapeutic-equivalence code, and marketing status.
ApplicationApplicantApprovedStrengthsTE codeStatus
ANDA 065089TevaMay 25, 20042ABPrescription
ANDA 065162TevaMar 12, 20041ABPrescription
ANDA 065189SandozAug 23, 20051ABPrescription
ANDA 065205TevaFeb 09, 20052—Prescription
ANDA 090227SandozApr 21, 20101ABPrescription
ANDA 091569Aurobindo Pharma LtdJan 20, 20122ABPrescription
ANDA 065064SandozMar 15, 20021ABPrescription
ANDA 065065Chartwell RxApr 18, 20022—Discontinued
ANDA 065066SandozJun 05, 20022ABPrescription
ANDA 065093Sandoz IncNov 21, 20021ABPrescription
ANDA 065096Teva Pharms USAOct 29, 20021ABPrescription
ANDA 065098Sandoz IncDec 16, 20022ABPrescription
ANDA 065101TevaOct 30, 20021ABPrescription
ANDA 065102Sun Pharm Inds LtdSep 17, 20021—Discontinued
ANDA 065109Sun Pharm Inds LtdNov 04, 20021—Discontinued
ANDA 065117Sandoz IncNov 27, 20021—Discontinued
ANDA 065132Sun Pharm Inds LtdMar 19, 20032—Discontinued
ANDA 065161Sun Pharm Inds LtdDec 03, 20032—Discontinued
ANDA 065191Hikma PharmsJan 25, 20052ABPrescription
ANDA 065207Sun Pharm Inds LtdJan 30, 20071—Discontinued
ANDA 065317Apotex IncOct 20, 20081—Discontinued
ANDA 065333Apotex IncFeb 24, 20092—Discontinued
ANDA 065358Sandoz IncAug 13, 20071ABPrescription
ANDA 065373Hikma PharmsNov 09, 20071ABPrescription
ANDA 065420CiplaDec 02, 20131ABPrescription
ANDA 065431CiplaNov 25, 20081ABPrescription
ANDA 091568Aurobindo Pharma LtdJan 20, 20121ABPrescription
ANDA 201090Aurobindo Pharma LtdDec 20, 20112ABPrescription
ANDA 201091Aurobindo Pharma LtdDec 20, 20111ABPrescription
ANDA 203824Hikma PharmsAug 23, 20161ABPrescription
ANDA 204755Micro Labs Ltd IndiaDec 30, 20161ABPrescription
ANDA 205187Micro Labs Ltd IndiaMay 21, 20212ABPrescription
ANDA 205707Micro Labs Ltd IndiaDec 30, 20162ABPrescription
ANDA 209351Deva Holding AsSep 13, 20231ABPrescription
ANDA 209371Aurobindo PharmaApr 19, 20192ABPrescription
ANDA 209991Deva Holding AsSep 15, 20231ABPrescription
ANDA 209992Deva Holding AsSep 15, 20231ABPrescription
ANDA 210374Deva Holding AsNov 29, 20231ABPrescription
ANDA 210416Deva Holding AsDec 11, 20231ABPrescription
ANDA 217805Micro LabsDec 08, 20231ABPrescription

Active-ingredient family

Brand + generics

Generic (ANDA) of Amoxicillin; Clavulanate Potassium

View full Amoxicillin; Clavulanate Potassium family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Amoxicillin And Clavulanate Potassium: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of ANDA 065063 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo